MORGAN STANLEY PLC/CALL/MODERNA/167.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 20:50:50 28/06/2024 BST | ||
| 0.61 EUR | -6.15% |
|
| Current month | -57.04% | ||
| 1 month | -68.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.61 | -6.15% |
| 27/06/24 | 0.65 | -7.14% |
| 26/06/24 | 0.7 | -38.05% |
| 25/06/24 | 1.13 | 0.00% |
| 24/06/24 | 1.13 | +6.60% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB32JU |
| ISIN | DE000MB32JU0 |
| Date issued | 01/02/2023 |
| Strike | 167.5 $ |
| Maturity | 20/12/2024 (173 Days) |
| Parity | 10 : 1 |
| Emission price | 6.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.08 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.05 € |
| Spread % | 7.46% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
